Novo nordisk a/s: oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the soul trial

BagsvÆrd, denmark, 21 october 2024 — novo nordisk today announced the headline results from the soul cardiovascular outcomes trial. the double-blinded, randomised trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (mace). the trial enrolled 9,650 people with type 2 diabetes and established cardiovascular disease (cvd) and/or chronic kidney disease (ckd). as part of standard of care, 49% of patients received sglt2i at some point during the trial.
NVO Ratings Summary
NVO Quant Ranking